Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real-World Study.

IF 1.8 4区医学 Q3 OPHTHALMOLOGY

Journal of Ophthalmology Pub Date : 2024-06-25 DOI:10.1155/2024/7645490

Tetsuya Muto,Masaaki Sakamoto,Shigeki Machida,Shinichiro Imaizumi,Tetsuju Sekiryu

{"title":"Effect of Vitreous Reflux after Intravitreal Aflibercept Injection for Macular Edema with Branch Retinal Vein Occlusion: A Real-World Study.","authors":"Tetsuya Muto,Masaaki Sakamoto,Shigeki Machida,Shinichiro Imaizumi,Tetsuju Sekiryu","doi":"10.1155/2024/7645490","DOIUrl":null,"url":null,"abstract":"Purpose\r\nThis study aimed to evaluate the therapeutic effect of vitreous reflux (VR) after intravitreal aflibercept injection (IVAI) for macular edema (ME) following naïve branch retinal vein occlusion (BRVO).\r\n\r\nMethods\r\nEighty patients with ME following BRVO were divided into three groups according to the conjunctival bleb diameter after IVAI as follows: group A (no VR), group; B (<3 mm VR), and group C (>3 mm VR). Each patient received single IVAI. The treatment response was evaluated with the best-corrected visual acuity (BCVA) and optical coherence tomography measurements of the retinal foveal thickness (RFT) before treatment and 1 month after the first injection. RFT >375 μm was defined as recurrence and received additional IVAI. The recurrence rate of ME and total numbers of IVAI were investigated at 12 months.\r\n\r\nResults\r\nThe BCVA values at 1 month were 0.17 ± 0.29 in group A (n = 41), 0.18 ± 0.17 in group B (n = 18), and 0.19 ± 0.26 in group C (n = 21). The RFT at 1 month were 270 ± 45 μm in group A, 279 ± 24 μm in group B, and 290 ± 43 μm in group C, respectively. ME recurred in 29 out of 41 patients in group A, 15 out of 18 in group B, and 14 out of 21 in group C. The total numbers of IVAI were 2.50 ± 1.24 in group A, 2.59 ± 1.06 in group B, and 2.29 ± 1.27 in group C, respectively. In the above mentioned comparisons, no significant differences were found following an IVAI (P > 0.05).\r\n\r\nConclusions\r\nVR after IVAI did not affect the therapeutic effect in patients with ME following BRVO. Thus, we do not need to pay excess attention to VR in the case of IVAI.","PeriodicalId":16674,"journal":{"name":"Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2024/7645490","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose This study aimed to evaluate the therapeutic effect of vitreous reflux (VR) after intravitreal aflibercept injection (IVAI) for macular edema (ME) following naïve branch retinal vein occlusion (BRVO). Methods Eighty patients with ME following BRVO were divided into three groups according to the conjunctival bleb diameter after IVAI as follows: group A (no VR), group; B (<3 mm VR), and group C (>3 mm VR). Each patient received single IVAI. The treatment response was evaluated with the best-corrected visual acuity (BCVA) and optical coherence tomography measurements of the retinal foveal thickness (RFT) before treatment and 1 month after the first injection. RFT >375 μm was defined as recurrence and received additional IVAI. The recurrence rate of ME and total numbers of IVAI were investigated at 12 months. Results The BCVA values at 1 month were 0.17 ± 0.29 in group A (n = 41), 0.18 ± 0.17 in group B (n = 18), and 0.19 ± 0.26 in group C (n = 21). The RFT at 1 month were 270 ± 45 μm in group A, 279 ± 24 μm in group B, and 290 ± 43 μm in group C, respectively. ME recurred in 29 out of 41 patients in group A, 15 out of 18 in group B, and 14 out of 21 in group C. The total numbers of IVAI were 2.50 ± 1.24 in group A, 2.59 ± 1.06 in group B, and 2.29 ± 1.27 in group C, respectively. In the above mentioned comparisons, no significant differences were found following an IVAI (P > 0.05). Conclusions VR after IVAI did not affect the therapeutic effect in patients with ME following BRVO. Thus, we do not need to pay excess attention to VR in the case of IVAI.

查看原文本刊更多论文

玻璃体内注射 Aflibercept 治疗视网膜静脉分支闭塞性黄斑水肿后玻璃体回流的影响：真实世界研究。

目的本研究旨在评估玻璃体回流（VR）在玻璃体内注射阿弗利百普（aflibercept）（IVAI）治疗新生视网膜分支静脉闭塞（BRVO）后黄斑水肿（ME）的疗效。方法根据IVAI后结膜虹膜直径的不同，将80例BRVO后ME患者分为三组：A组（无VR）、B组（3 mm VR）。每名患者接受一次 IVAI。治疗前和首次注射后 1 个月，用最佳矫正视力（BCVA）和光学相干断层扫描测量视网膜眼窝厚度（RFT）来评估治疗反应。RFT >375 μm被定义为复发，并接受额外的IVAI治疗。结果 A组（41 人）1 个月后的 BCVA 值为 0.17 ± 0.29，B 组（18 人）为 0.18 ± 0.17，C 组（21 人）为 0.19 ± 0.26。1 个月时，A 组的 RFT 分别为 270 ± 45 μm，B 组为 279 ± 24 μm，C 组为 290 ± 43 μm。A组41名患者中有29人复发ME，B组18人中有15人复发ME，C组21人中有14人复发ME，IVAI总数分别为2.50±1.24（A组）、2.59±1.06（B组）和2.29±1.27（C组）。在上述比较中，IVAI 后无明显差异（P > 0.05）。因此，在进行 IVAI 时，我们无需过分关注 VR。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ophthalmology MEDICINE, RESEARCH & EXPERIMENTAL-OPHTHALMOLOGY

CiteScore

4.30

自引率

5.30%

发文量

194

审稿时长

6-12 weeks

期刊介绍： Journal of Ophthalmology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to the anatomy, physiology and diseases of the eye. Submissions should focus on new diagnostic and surgical techniques, instrument and therapy updates, as well as clinical trials and research findings.

文献相关原料

公司名称	产品信息	采购帮参考价格